Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenu archivé le 2024-05-24

Animal brucellosis : genetically engineered live vaccines against b. melitensis (BRU-VAC)

CORDIS fournit des liens vers les livrables publics et les publications des projets HORIZON.

Les liens vers les livrables et les publications des projets du 7e PC, ainsi que les liens vers certains types de résultats spécifiques tels que les jeux de données et les logiciels, sont récupérés dynamiquement sur OpenAIRE .

Livrables

The product is a new rough (R) vaccine against Brucella melitensis infection of sheep. This R vaccine eliminates the diagnostic problems caused by the classical Rev 1 vaccine in the standard serological tests (rose bengal and complement fixation). A modified iELISA protocol offered as ancillary serodiagnostic tool also reduces the residual serological interference in this assay. The R vaccine is based on the mutation of a gene selected through experiments in laboratory models and in sheep among 16 potentially interesting genes. It carries markers for easy typing and comes with a PCR typing protocol. This R vaccine is safer than Rev 1 for humans and is not resistant to the antibiotics used to treat human brucellosis, a disadvantage of the classical Rev 1 vaccine and of previously described R vaccines. Protection afforded by the new vaccine is much higher than that published for other R vaccines in sheep. It does not reach the levels of protection afforded by vaccine Rev 1 (58% versus 100% protection in the controlled experiment carried out) but may be an alternative prophylactic tool under special circumstances.

Recherche de données OpenAIRE...

Une erreur s’est produite lors de la recherche de données OpenAIRE

Aucun résultat disponible